for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Mesoblast limited (ADR)

MESO.O

Latest Trade

11.81USD

Change

0.00(0.00%)

Volume

112

Today's Range

--

 - 

--

52 Week Range

3.12

 - 

20.57

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest News

BRIEF-Mesoblast Says Expanded Access Protocol Initiated For Compassionate Use Of Remestemcel-L In Children

* EAP INITIATED FOR COMPASSIONATE USE OF REMESTEMCEL-L IN CHILDREN WITH MULTISYSTEM INFLAMMATORY SYNDROME ASSOCIATED WITH COVID-19 Source text for Eikon: Further company coverage:

BRIEF-Mesoblast: Remestemcel-L Shows Improvement In Patients With Inflammatory Lung Disease

* MESOBLAST LTD - REMESTEMCEL-L IMPROVES RESPIRATORY AND FUNCTIONAL OUTCOMES IN PATIENTS WITH INFLAMMATORY LUNG DISEASE Source text for Eikon: Further company coverage:

BRIEF-Mesoblast Qtrly Loss Attributable US$15.3 Mln

* QTRLY LOSS ATTRIBUTABLE US$15.3 MILLION VERSUS LOSS OF US$25 MILLION

BRIEF-Mesoblast Successfully Completes Financing To Scale-Up Manufacturing Of Remestemcel-L For Covid-19 Ards

* MESOBLAST SUCCESSFULLY COMPLETES FINANCING TO SCALE-UP MANUFACTURING OF REMESTEMCEL-L FOR COVID-19 ARDS Source text for Eikon: Further company coverage:

BRIEF-Mesoblast Completes Financing To Scale-Up Manufacturing Of Remestemcel-L For COVID-19 ARDS

* COMPLETES FINANCING TO SCALE-UP MANUFACTURING OF REMESTEMCEL-L FOR COVID-19 ARDS

BRIEF-Mesoblast Says First Patients Dosed In Controlled Trial Of Remestemcel-L For Covid-19 Acute Respiratory Distress Syndrome

* FIRST PATIENTS DOSED IN PHASE 2/3 RANDOMIZED CONTROLLED TRIAL OF MESOBLAST’S REMESTEMCEL-L FOR COVID-19 ACUTE RESPIRATORY DISTRESS SYNDROME Source text for Eikon: Further company coverage:

BRIEF-Mesoblast - Phase 2/3 Randomized Controlled Trial Of Remestemcel-L In 300 Patients With COVID-19 Acute Respiratory Distress Syndrome Begins Enrollment

* PHASE 2/3 RANDOMIZED CONTROLLED TRIAL OF REMESTEMCEL-L IN 300 PATIENTS WITH COVID-19 ACUTE RESPIRATORY DISTRESS SYNDROME BEGINS ENROLLMENT

BRIEF-Mesoblast Says Phase 2/3 Trial Of Drug On COVID-19 ARDS Patients Begins Enrollment

* PHASE 2/3 RANDOMIZED CONTROLLED TRIAL OF REMESTEMCEL-L IN 300 PATIENTS WITH COVID-19 ACUTE RESPIRATORY DISTRESS SYNDROME BEGINS ENROLLMENT Source text for Eikon: Further company coverage:

Australia shares flat as dealers weigh coronavirus impact

* Australian stocks down for week after 4 straight weekly gains

BRIEF-Mesoblast Announces 83% Survival In COVID-19 Patients With ARDS Treated With Remestemcel-L

* 83% SURVIVAL IN COVID-19 PATIENTS WITH MODERATE/SEVERE ACUTE RESPIRATORY DISTRESS SYNDROME TREATED WITH CO'S CELL THERAPY REMESTEMCEL-L Source text https://reut.rs/351jWJX Further company coverage:

BRIEF-Mesoblast To Present Positive Clinical Outcomes Using Remestemcel-L In Patients With Inflammatory Lung Disease

* MESOBLAST TO PRESENT POSITIVE CLINICAL OUTCOMES USING REMESTEMCEL-L IN PATIENTS WITH INFLAMMATORY LUNG DISEASE AT 2020 INTERNATIONAL SOCIETY OF CELL AND GENE THERAPY ANNUAL MEETING Source text for Eikon: Further company coverage:

BRIEF-Mesoblast Says Remestemcel-L To Be Evaluated In Phase 2/3 Coronavirus Trial

* REMESTEMCEL-L WILL BE FORMALLY EVALUATED IN RANDOMIZED, PLACEBO-CONTROLLED TRIAL IN PATIENTS WITH ARDS CAUSED BY CORONAVIRUS Source text for Eikon: Further company coverage:

BRIEF-U.S. FDA Clears IND For Use Of Mesoblast's Remestemcel In COVID-19 ARDS Patients

* U.S. FDA CLEARS IND FOR REMESTEMCEL USE IN COVID-19 ARDS PATIENTS Source text for Eikon: Further company coverage:

BRIEF-Mesoblast Says U.S. FDA Accepted For Priority Review Co's Biologics License Application Filing For Ryonciltm (Remestemcel-L)

* U.S. FDA ACCEPTED FOR PRIORITY REVIEW CO'S BIOLOGICS LICENSE APPLICATION FILING FOR RYONCILTM (REMESTEMCEL-L) Source text for Eikon: Further company coverage:

BRIEF-Mesoblast To Evaluate Anti-Inflammatory Cell Therapy Remestemcel-L For Covid-19

* MESOBLAST TO EVALUATE ANTI-INFLAMMATORY CELL THERAPY REMESTEMCEL-L FOR TREATMENT OF COVID-19 LUNG DISEASE

BRIEF-Mesoblast To Evaluate Anti-Inflammatory Cell Therapy For COVID-19

* TO EVALUATE ITS ANTI-INFLAMMATORY CELL THERAPY REMESTEMCEL-L FOR TREATMENT OF COVID-19 LUNG DISEASE Source text for Eikon: Further company coverage:

BRIEF-Mesoblast Says Ryoncil Expected To Be Launched In United States In 2020

* RYONCIL IS EXPECTED TO BE LAUNCHED IN UNITED STATES IN 2020 Source text for Eikon: Further company coverage:

BRIEF-Mesoblast HY Loss Attributable $30.1 Mln

* HY LOSS ATTRIBUTABLE $30.1 MILLION VERSUS LOSS OF $44.1 MILLION

BRIEF-Mesoblast Announces Clinically Meaningful Outcomes Using Remestemcel-L In Patients With Chronic Graft Versus Host Disease

* MESOBLAST LTD ANNOUNCES CLINICALLY MEANINGFUL OUTCOMES USING REMESTEMCEL-L IN PATIENTS WITH CHRONIC GRAFT VERSUS HOST DISEASE

BRIEF-Mesoblast Says Co & Lonza Enter Agreement For Commercial Manufacture Of Co's Allogeneic Cell Therapy

* CO & LONZA ENTER AGREEMENT FOR COMMERCIAL MANUFACTURE OF MESOBLAST’S POTENTIAL FIRST UNITED STATES ALLOGENEIC CELL THERAPY

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up